Thorax:从低剂量CT扫描和吸烟因素预测肺癌的可行性

2019-03-26 xiangting MedSci原创

LCCM具有作为肺癌预测因子的前途,因为它相对现有模型有显著的改善。

低剂量CT(LDCT)目前用于高危人群的肺癌筛查,以早期诊断肺癌。然而,96%检测到结节的个体是假阳性。

为了从临床、人口学和LDCT特征开发有效的早期肺癌预测因子,研究人员对218名肺癌或良性结节受试者进行了研究。使用概率图模型(PGMs)整合来自匹兹堡肺部筛查研究队列92名受试者(训练队列)的人口学、临床数据和LDCT特征。

学习后的PGMs确定了3个直接(因果)与恶性结节和最大良性结节相关的变量,并用它们构建了肺癌因果模型(LCCM),该模型在126名受试者的单独队列中得到验证。结节、血管数量和受试者戒烟年数足以区分恶性结节与良性结节。在训练和验证队列中与现有预测因子进行比较表明:(1)结合LDCT扫描特征大大提高了预测的准确性;(2)LCCM改善癌症检测优于现有的方法,包括Brock简约模型(p<0.001)。值得注意的是,周围血管数量,这个以前未在预测模型中使用的特征,显著提高了预测效率。根据验证队列结果,LCCM能够识别30%的良性结节,而没有错误分类癌结节的风险。

LCCM具有作为肺癌预测因子的前途,因为它相对现有模型有显著的改善。在更大的前瞻性研究中进行验证后,LCCM有助于减少不必要的随访和手术。

原始出处:

Vineet K Raghu. Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models. Thorax. 12 March 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022940, encodeId=963f20229403d, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Fri May 10 18:59:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423977, encodeId=6a2114239e737, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480539, encodeId=53ca1480539d4, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618770, encodeId=6cd01618e70fb, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022940, encodeId=963f20229403d, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Fri May 10 18:59:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423977, encodeId=6a2114239e737, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480539, encodeId=53ca1480539d4, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618770, encodeId=6cd01618e70fb, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022940, encodeId=963f20229403d, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Fri May 10 18:59:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423977, encodeId=6a2114239e737, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480539, encodeId=53ca1480539d4, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618770, encodeId=6cd01618e70fb, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022940, encodeId=963f20229403d, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Fri May 10 18:59:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423977, encodeId=6a2114239e737, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480539, encodeId=53ca1480539d4, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618770, encodeId=6cd01618e70fb, content=<a href='/topic/show?id=aa2e5463db' target=_blank style='color:#2F92EE;'>#CT扫描#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5463, encryptionId=aa2e5463db, topicName=CT扫描)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3819951332, createdName=ms6323715314570549, createdTime=Thu Mar 28 00:59:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]

相关资讯

这名患者中,肺癌引起了什么并发症?

患者,男,70岁,进行性头、颈、手臂和上胸部水肿伴呼吸困难、颈胸静脉扩张而入院。患者行18F-FDG PET/CT显像。

Thorax:肺癌后第二原发癌和更高级吸烟相关原发癌的发病率

从初次诊断开始,肺癌幸存者后续肺癌、喉癌、头颈癌和食管鳞状细胞癌发病率升高至少持续10年。

Sci Transl Med:KRAS突变型肺癌或喜迎MEK抑制剂联合用药

大约30%的癌症存在KRAS的活化突变,其通过称为MAPK的信号传导途径触发肿瘤发生与进展。虽然目前还没有直接针对KRAS的药物成功,但已经开发出针对MEK的靶向治疗。

Thorax:使用NLST数据对Brock模型进行外部验证和重新校准,以预测肺结节中癌症的概率

虽然Brock模型在NLST数据集上验证时达到了高AUC,但该模型得益于更新和重新校准。

JAMA Surg:退伍军人事务部肺癌视频辅助胸腔镜肺切除术的使用

与教学医院一样,退伍军人事务部中大部分的肺切除术采用视频辅助胸腔镜手术完成。

Thorax:影像学肺气肿在肺癌风险评估中的作用

影像学肺气肿是肺癌诊断的独立预测因子,其有助于指导合适患者进一步筛查的决策。